Fexiar Trio Tablet SR is a combination medication containing Ambroxol (75mg), Levocetirizine (5mg), and Montelukast (10mg), designed to provide comprehensive relief from respiratory conditions characterized by cough, allergy, and inflammation. Ambroxol acts as a mucolytic agent, helping to thin and loosen mucus in the airways, facilitating easier expectoration and improving breathing. Levocetirizine, a second-generation antihistamine, effectively reduces allergic symptoms such as sneezing, runny nose, and itching by blocking histamine receptors without causing significant drowsiness. Montelukast, a leukotriene receptor antagonist, helps in preventing bronchoconstriction and inflammation, making it beneficial for managing asthma and allergic rhinitis. The sustained-release formulation ensures a gradual and prolonged therapeutic effect, enhancing patient compliance by reducing dosing frequency. Fexiar Trio Tablet SR is typically prescribed for patients suffering from chronic respiratory conditions like asthma, allergic rhinitis, and bronchitis, where multiple pathways contribute to symptoms. It is important to use this medication under medical supervision, as dosage adjustments may be necessary based on individual health status and response. Common side effects may include mild gastrointestinal discomfort or headache, and patients should inform their healthcare provider of any pre-existing conditions or concurrent medications to avoid potential interactions.